Open AccessEfficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia
Author(s) -
Milena Božić,
Ksenija Bojović,
Milotka Fabri,
Darko Nožić,
Bojan Trkulja,
Ivana Milošević
Publication year - 2012
Publication title -
srpski arhiv za celokupno lekarstvo
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 17
eISSN - 2406-0895
pISSN - 0370-8179
DOI - 10.2298/sarh1208448b
Subject(s) - medicine , ribavirin , pegylated interferon , gastroenterology , peginterferon alfa 2a , hbsag , hepatitis c virus , hepatitis c , immunology , virus , hepatitis b virus
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. Pegylated interferon alfa-2a or 2b (PEG IFN alfa-2a or 2b) and ribavirin (RBV) represent a standard treatment of chronic hepatitis C (CHC). Sustained virological response (SVR), defined as continued undetectable HCV RNA 24 weeks after completion of treatment, is universally considered as an indicator of treatment efficacy.